We are a team of health care professionals dedicated and committed to treating patients with brain tumours and improving the overall outcomes and management of the disease burden. We have a vision and pursuit to understand why tumours develop and to create new treatment strategies.


Dr. Gelareh Zadeh is a Professor at the Department of Surgery, University of Toronto, and Head of Neurosurgery at Toronto Western Hospital. She leads Surgical Oncology at Princess Margaret Cancer Center and is a Senior Scientist at Princess Margaret Cancer Research Institute.

She holds the Wilkins Family Chair in Brain Tumor Research focusing on building surgical clinical trials for brain tumor patients.

Internationally, she is the President of the Society for Neuro-Oncology and Editor-in-Chief of Neuro-Oncology Advances, an open access journal of Society of Neuro-Oncology and European Association of Neuro-Oncology.

Her clinical practice focuses on Skull Base Neuro-Oncology, with dedicated general brain tumour clinic and many multidisciplinary clinics that she has established at UHN such as skull base, pituitary, brain metastases, gamma knife, and neurofibromatosis clinic.



Drs. Gelareh Zadeh  and Farshad Nassiri shares promising results. 

Combination therapy shows survival benefits for recurrent glioblastoma patients, surpassing efficacy threshold despite missing primary endpoint. Further research planned to explore its potential in randomized trials. Read more here

A new international study from UHN neurosurgeons using a novel approach to treating glioblastoma shows great promise for patients

Drs. Farshad Nassiri and Gelareh Zadeh published the results of a Phase 1/2 clinical trial in Nature Medicine last week. They investigated a therapy that combines injecting an oncolytic virus, which targets and kills cancer cells, directly into a tumour, using intravenous immunotherapy. They found this novel combination therapy can kill the tumour in select patients, extending their survival. “We are cautiously optimistic about the long-term clinical benefits for patients,” Dr. Zadeh told UHN News. UHN was the only Canadian institution involved in this study and treated the majority of the patients enrolled in the trial. Read UHN News for more and be sure to watch this video exploring how these scientists seek to move the needle for glioblastoma patients.

Nassiri, F., Liu, J., Patil, V. et al. A clinically applicable integrative molecular classification of meningiomas. Nature 597, 119–125 (2021). https://doi.org/10.1038/s41586-021-03850-3

Dr. Gelareh Zadeh discusses groundbreaking brain cancer test

Watch this insightful story via @globalnewsto for a glimpse behind-the-scenes into her world @gelarehzadeh @KBI_UHN @UofTNeuroSurge